Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus
Sponsor: Sisli Hamidiye Etfal Training and Research Hospital
Summary
A randomized, single-blind, controlled trial to evaluate the effects of neural therapy on tinnitus severity, disability, and quality of life in patients with tinnitus. The study is planned to be conducted between December 2025 and March 2026. The sample size is 30 patients. The number of centers is 1. The study duration is 3 months.
Official title: A Randomized, Single-blind, Controlled Trial to Evaluate the Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-03-01
Completion Date
2026-05-26
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
Neural Therapy of Huneke
The aim for tinnitus and facial pain is to regulate the trigeminal system and autonomic balance. Concentration used: Lidocaine 0.5%. The auriculotemporal, infraorbital, zygomaticotemporal, and stellate regions were targeted. Puncture applications: 0.3-0.5 mL will be administered behind the ear, around the mastoid process, behind the tragus, and in the temporomandibular region. If necessary, the stellate ganglion area can be supplemented with regulation injections. Negative aspiration and aseptic technique will be applied before each application. Transient mild dizziness or local redness may occur after application. To avoid the risk of systemic toxicity, the total dose should generally not exceed a maximum of 200 mg of lidocaine.
Betahistine 24 mg bid (Betaserc)
Patients will be given Betahistine 16-48 mg/day in divided doses, depending on their weight and disease severity.